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Abstract
Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and
endothelin receptor antagonist is recommended for most patients with
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intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and
REPLACE studies suggest that switching from a PDE5i to a soluble guanylate
cyclase (sGC) activator may provide clinical improvement in this situation.
The optimal approach to escalation or transition of therapy in this or other
scenarios is not well defined. We developed an expert consensus statement on
the transition to sGC and other treatment escalations and transitions in PAH
using a modified Delphi process. The Delphi process used a panel of 20
physicians with expertise in PAH. Panelists answered three questionnaires on
the management of treatment escalations and transitions in PAH. The initial
questionnaire included open‐ended questions. Later questionnaires consolidated the responses into statements that panelists rated on a Likert scale from
−5 (strongly disagree) to +5 (strongly agree) to determine consensus. The
Delphi process produced several consensus recommendations. Escalation
should be considered for patients who are at high risk or not achieving
treatment goals, by adding an agent from a new class, switching from oral to
parenteral prostacyclins, or increasing the dose. Switching to a new class or
within a class should be considered if tolerability or other considerations
unrelated to efficacy are affecting adherence. Switching from a PDE5i to an
SGC activator may benefit patients with intermediate risk who are not
improving on their present therapy. These consensus‐based recommendations
may be helpful to clinicians and beneficial for patients when evidence‐based
guidance is unavailable.
KEYWORDS

adherence, goal directed, tolerability, treatment escalation, treat to target

I N T R O D U C TI O N
Pulmonary arterial hypertension (PAH) causes significant morbidity and mortality despite important improvements in understanding the pathophysiology and therapy
of the disease over the past two decades. Treatment can
prolong survival, delay progression, and improve function and quality of life.
Current guidelines recommend a treat‐to‐target
strategy aimed at achieving, as quickly as possible,
clinical and laboratory findings that are associated with
a low risk of 1‐year mortality as defined by clinical and
hemodynamic criteria.1,2 Patients at initially low or
intermediate risk typically receive dual combination
therapy, including a phosphodiesterase‐5 inhibitor
(PDE5i) and an endothelin receptor antagonist (ERA)
to target the nitric oxide/cyclic GMP and endothelin
pathways, respectively. An oral or infusion (SQ/IV)
prostacyclin analog (PCA) is added for patients initially
at high risk and to escalate therapy in patients who do
not achieve low‐risk status after 3–6 months of
treatment.2

Soluble guanylate cyclase (sGC) activators target the
nitric oxide/cyclic GMP pathway by enhancing cGMP
production. This contrasts with PDE5i agents, which
slows cGMP degradation. The RESPITE and REPLACE
studies examined the impact of switching from a PDE5i
to riociguat, an sGC activator, in patients at intermediate
risk who had not reached low‐risk status on a PDE5i
alone or in combination with an ERA. The trials found
that switching to an sGC activator is a therapeutic option
for escalation because significantly more patients improved clinically after 24 weeks of therapy.3,4 REPLACE
used a prospective, randomized, open‐label, blinded
endpoints design, so the strength of the resulting
evidence does not reach that of a randomized double‐
blind trial. Thus, careful clinical judgment is needed in
applying these results to clinical practice.5 Because the
REPLACE trial was published recently, the guidelines for
the treatment of PAH have not yet incorporated these
findings. In the absence of robust evidence or guideline
recommendations, expert advice can provide considerable benefit to clinicians and patients by providing
informed guidance. This Delphi process aimed to develop
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an expert consensus on escalations and transitions of
therapy in patients with PAH, with consideration of
when sGC activators might be used to replace PDE5
inhibitors.

METHODS
This study used a modified Delphi process to develop and
define expert consensus recommendations on treatment
selection for escalation and transitions of therapy in
PAH. This Delphi process is a structured method for
group decision making that was developed by Delbecq et al. in 1975 and is now widely used in
pulmonology and other medical settings.6–14
The study was conceived by the lead and senior
authors, who oversaw the recruitment of the Delphi
panelists, developed the three scenarios used in the
surveys, moderated the questionnaires, and managed the
conduct of the study. The panelists were selected from
physicians with particular expertise and interest in PAH,
based on their specialties and experience in treating
PAH. Panelists were included as coauthors if they
completed one or both of the first 2 surveys and the
third survey, and reviewed and approved each stage of

F I G U R E 1 The modified Delphi process
used in the study
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the study and the final manuscript. All coauthors met the
International Committee of Medical Journal Editors' criteria for authorship.
Figure 1 summarizes the modified Delphi process
used in the study. The process is based on three surveys.
Survey 1 included primarily open‐ended questions about
panelists’ general approach to treatment selection, and
whether and how they would escalate therapy in
three common scenarios: a patient on dual therapy, a
patient on triple oral therapy, and a patient on triple
therapy including an IV PCA. Copies of the 2015
guidelines for the diagnosis and treatment of pulmonary
hypertension developed by the European Society for
Cardiology and European Respiratory Society and the
2019 update based on the World Symposium on
Pulmonary Hypertension (WSPH) held in 2018 were
circulated to panelists with Survey 1.1,2 Survey 2
consisted primarily of a series of statements based on
panelist's responses to Survey 1. The statements were
developed by consolidating and clarifying the management options described in panelists’ answers to the
questions in Survey 1. Panelists were asked to rate their
agreement with each statement using a Likert scale
ranging from −5 (strongly disagree) to +5 (strongly agree).
Survey 3 was identical to Survey 2, except that panelists
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were provided with their own answers to Survey 2, the
mean and standard deviation of the group's answers, and
whether consensus was achieved for each answer. This
additional information is intended to promote consensus
by making participants aware of the overall group
opinion. The final aggregate results were circulated to
all participants for review and comment. Panelist
anonymity was maintained throughout the process, and
there was no group meeting (as used in some Delphi
processes). Full results for Survey 3 are provided in the
Supporting Information Appendix.
The extent of consensus was evaluated using Likert
scale questions that asked panelists to rate their
agreement with statements using a scale from −5
(strongly disagree) to 5 (strongly agree). Panelists were
considered to have reached a consensus if the mean
Likert scale score was ≤−2.5 or ≥2.5, with an SD that did
not cross 0.

RESU LTS
The Delphi panel initially comprised 22 panelists. Of
these, 20 panelists completed the third survey and met
the other requirements for authorship. The final survey
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included 232 statements, of which consensus was
reached on 129 (56%).

General approach to treatment selection
Panelists reached a consensus that multiple factors are
important in selecting a treatment regimen for patients
with PAH (Figure 2), with the strongest consensus for
considering the severity of disease and the risk profile,
clinical trial evidence of efficacy and safety, and the
physician's clinical experience. However, panelists considered all of the factors important and that their
importance varies between patients. The only factors
that did not reach consensus were cost and geography
(e.g., distance from the treatment center).
Panelists reached a consensus that patient‐centered
factors (e.g., tolerability, patient preference, and financial considerations) should be considered in a shared
decision‐making process that integrates those patient
factors, clinical data, and clinician experience. Panelists
agreed that most newly diagnosed patients should be
treated with combination oral therapy, with a Likert
scale score (mean ± SD) of 4.30 ± 0.96. Most panelists
agreed with the treatment algorithm presented at the

F I G U R E 2 Delphi consensus results: factors
important in selecting a treatment regimen
(ranked by the mean consensus score)
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6th WSPH. Panelists reached a consensus that expert
advice and clinical experience should guide therapeutic
recommendations when no clinical evidence is available
(3.38 ± 1.03).

Approach to deciding whether to escalate
or switch therapy
Panelists reached a consensus that risk level is an
important factor in deciding whether to escalate or
switch therapy (4.37 ± 0.82), that escalation of therapy is
needed for patients whose REVEAL risk score is greater
than low risk and does not improve (3.53 ± 1.27), and
that symptoms, World Health Organization functional
class (FC), echocardiography characteristics, and serum
brain natriuretic peptide levels are key parameters for
building a clinical gestalt that will drive decision‐making.
Factors considered by panelists to have important roles
in the decision to switch or escalate are listed in Figure 3.
Similar to the selection of an initial therapy, multiple

F I G U R E 3 Delphi consensus results: role of
key factors considered in decisions on escalation
or switching. FC, functional class; 6MWD,
6‐min walk distance; PAH, pulmonary arterial
hypertension; WHO, World Health
Organization

5 of 13

factors should be considered, including patient‐related
factors (such as the severity of disease, rate of progression), exercise capacity (but only 6‐min walk testing),
right ventricular function, and pulmonary hemodynamics, which was considered most important. Interestingly, there was no consensus regarding patient age.
There was a strong consensus that patient buy‐in (the
patient's agreement with the physician's recommendation) is a key factor in treatment selection, with a weaker
consensus that patient preference (allowing the patient to
select therapy) is a key factor.

Clinical scenario: A patient on dual
therapy who requires escalation
Panelists considered several clinical scenarios involving a
decision to escalate or switch PAH therapy to identify
key considerations in the decision.
In the first scenario, a hypothetical patient receiving two‐drug combination therapy has been stable with
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a low‐risk profile for several months, but has progressed with an increased risk level at the most recent
follow‐up. Panelists were asked to consider switching
to a new agent in the same class, switching one agent
to a new class, or initiating triple therapy by adding a
new agent. Figure 4 shows the results for statements
that reached consensus in this scenario. Switching to a
new agent in the same class could be considered if
tolerability, adherence, or logistical reasons were
impacting therapy. Switching to a new class might be
considered to manage intolerance or improve adherence, particularly if the switch could reduce side
effects and/or improve efficacy. The results from the
RESPITE and REPLACE studies support the possibility
of switching from a PDE5i to an sGC activator in this
situation.3,4 Adding a new class (especially a PCA)
rather than changing within the class should be
considered in patients who are higher risk, are
progressing or not reaching targets, or have progressed
to FC IV.
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Clinical scenario: A patient on oral triple
therapy who requires escalation
In this scenario, the hypothetical patient's symptoms
and FC are worsening while the patient is receiving
three‐drug oral combination therapy. Panelists were
asked to consider adjusting dosages, switching from a
PDE5i to an sGC activator, switching from oral to
parenteral PCAs, or switching one or more agents
within the same class.
Panelists reached a consensus that adjusting the
dosage of existing medications could be considered if
the patient is not already at the maximally tolerated
dose, if side effects are not significant and progression
is not rapid, if the patient has benefited from prior
dose increases, and if progression is mild, with no
signs of right heart failure (Figure 5). However, dose
adjustment is not appropriate if the patient is at higher
risk or rapidly worsening; parenteral therapy is
needed in this situation. Switching from a PDE5i to

F I G U R E 4 Escalation for a patient on dual
therapy: Delphi consensus results for selected
statements that reached consensus. FC,
functional class; PDE5i, phosphodiesterase‐5
inhibitor; sGC, soluble guanylate cyclase; WHO,
World Health Organization
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F I G U R E 5 Escalation for a patient on oral
triple therapy: Delphi consensus results for
selected statements that reached consensus. AE,
adverse event; FC, functional class; PCA,
prostacyclin analog; PDE5i, phosphodiesterase‐5
inhibitor; RHF, right‐sided heart failure; sGC,
soluble guanylate cyclase

an sGC activator could be considered if the patient is
already at the maximally tolerated dosages or if
parenteral prostanoids or full‐dose PDE5i are contraindicated, intolerable, or unacceptable to the patient.
It might also be considered in patients with a history
of good adherence who are experiencing mild worsening and agree to close monitoring. Switching medications in other classes were only considered if there was
intolerance or severe adverse effects. Panelists reached
a consensus on several conditions in which escalation
from oral to parenteral PCAs could be considered: FC
IV, rapid progression, high‐risk hemodynamics, right
heart failure, clinical worsening in moderate‐risk
patients, and intolerance of higher doses or intolerable
AEs of the existing medications.

Clinical scenario: A patient on triple
therapy including an SQ/IV PCA who
requires escalation
This scenario involves a hypothetical patient with
worsening symptoms and FC while receiving three‐
drug combination therapy including SQ/IV treprostinil.
Panelists were asked to consider adjusting dosages,
switching from a PDE5i to an sGC activator, switching
other agents within a class, or other treatment approaches (Figure 6). Panelists reached a consensus that
dosage adjustment could be considered if the patient is
not at the maximally tolerated dose of the three drugs,
particularly if invasive hemodynamic assessment by right
heart catheterization (RHC) finds a low cardiac output
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F I G U R E 6 Escalation for a patient on triple
therapy including SQ/IV treprostinil: Delphi
consensus results for statements that reached
consensus. FC, functional class; 6MWD, 6‐min
walk distance; PAH, pulmonary arterial
hypertension; PDE5i, phosphodiesterase‐5
inhibitor; QD, twice a day; RHC, right heart
catheterization; sGC, soluble guanylate cyclase;
TID, three times daily

and symptoms are worsening. Switching within a class
could be considered if there is intolerance to one agent.
There was a weak consensus for switching from
parenteral treprostinil to epoprostenol in patients who
were failing or intolerant of parenteral treprostinil.
Switching from a PDE5i to an sGC activator could be
considered if all three current medications are at their
maximum‐tolerated doses.
Alternative therapies in this situation include referral
for a lung transplant in appropriate candidates, palliative
care and hospice, and participation in a research study.
Pulmonary rehabilitation, aggressive diuretic management, and other therapies may be appropriate. Note that
a repeat evaluation including echocardiography, RHC,
and possibly additional imaging may be appropriate to
confirm the diagnosis.

DISCUSSION
This study used a modified Delphi method to develop
expert consensus recommendations on escalation and
transitions of therapy for patients with PAH, focusing on
the possibility of switching from a PDE5i to riociguat in
patients. Panelists reached a consensus that numerous

factors should be considered in selecting therapy, most
notably disease severity, the patient's risk profile, clinical
trial evidence, and the clinician's experience. Other
factors were considered important, but a few factors did
not reach consensus: cost, geography (patient's distance
from the clinician's practice), exercise testing other than
the 6‐min walk distance test, and patient age. Patient
preference was deemed important as was patient involvement in shared decision‐making, but patient “buy‐in” was
rated as even more important by panelists, suggesting that
advocating for the merit of therapy while participating in
shared decision‐making is paramount.
Since formal clinical guidelines aim to be evidence‐
based, they are limited to making recommendations that
have a strong basis in published data. Unfortunately,
limitations on time and resources, ethical considerations,
and challenges in enrolling sufficient numbers of
patients preclude the creation of guidelines on many
clinical questions. The evidence derived from studies on
risk assessment calculators and other trials favors a
strategy of escalating therapy to decrease patients’ risk
status.15–21 However, evidence to guide decisions on the
escalation of therapy in PAH, particularly blinded
comparative efficacy trials, is very limited. The lack of
evidence heightens the relevance of the comparative
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RESPITE and REPLACE trials. This study is an attempt
to capture the practical thought processes used by experts
to make these decisions and to try to understand the
reasoning behind those choices.
Panelists opined that PAH therapy should be
escalated in patients who are at high risk, in WHO FC
IV, are progressing/worsening, have signs of right heart
failure, or are not meeting treatment goals. In these
situations, patients on dual therapy should add a new
agent from a different class, with parenteral PCAs
preferred for patients in WHO FC IV. Patients on triple
oral therapy who need treatment escalation should first
maximize dosages of all medications, and, if there is no
improvement, consider switching from an oral PCA to
a parenteral PCA. Patients on triple therapy including an
IV PCA should optimize the doses and may consider
switching from SQ/IV treprostinil to IV epoprostenol.
When intolerability or nonadherence is an issue,
panelists felt it reasonable to consider switching to a new
agent in the same class, or (for dual therapy) switching to
a new class. For select patients in an intermediate‐risk
category who have not achieved low‐risk status while
receiving a PDE5i, the results of the RESPITE and
REPLACE studies suggest that switching from a PDE5i to
an sGC activator may also provide significant clinical
improvement.3,4 We did not directly address dual therapy
that included PCAs. In other scenarios involving PCAs,
the group suggested maximizing the dose of oral/IV
PCAs, and, in higher‐risk patients, switching to IV/SQ
from oral or inhaled PCAs or adding a third class of
medications.
Table 1 summarizes key consensus opinions. These
are generally aligned with guidelines from the ESC/ERS,
as updated in the 6th WSPH for risk stratification and
medical therapy of PAH.1,2 In broad outline, the WSPH
update of the ESC/ERS guidelines recommends continuing existing therapy for patients at low risk, escalating to
triple combination therapy for patients at intermediate
risk, and escalating to maximal medical therapy for
patients at intermediate or high risk in spite of triple
therapy. Other transitions might be considered to
improve the adverse event profile, convenience, or
compliance.1,2 Our consensus recommendations for
specific clinical scenarios align with these guidelines,
given that our hypothetical patients on dual therapy,
triple therapy, and triple therapy including an SQ/IV
PCA were initially at low, intermediate, and high risk,
respectively. The consensus recommendations provide
additional details on situations where transitions without
escalation might be appropriate. The ESC/ERS guidelines
state that there is insufficient evidence to recommend a
transition from a PDE5i to an sGC activator based on the
uncontrolled RESPITE trial. Data from the more recent
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T A B L E 1 Summary of key consensus opinions on how to
escalate therapy for PAH patients failing to achieve goals of
therapy
Patient on dual therapy
• Switching within a class or to a new class could be considered
if tolerance, side effects, logistics, patient preference, and so
on, are impacting therapy
• Switching from a PDE5i to an sGC activator could be
considered for patients failing to improve and/or with dose‐
limiting side effects from the PDE5i and at low‐to‐
moderate risk
• Adding an agent from a new class should be considered for
patients whose disease is progressing or who are not reaching
target goals
o For patients who are rapidly progressing, in a high‐risk
group, or in WHO FC IV, the added agent should be a
parenteral PCA
Patient on triple oral therapy
• Dose adjustment could be considered if side effects are not
significant and progression is not rapid, based on
hemodynamics and risk
• Switching from a PDE5i to an sGC activator could be
considered if the patient is not improving and all medications
are at the maximum‐tolerated dose, particularly in patients
with good adherence and mild symptom worsening, or if the
patient is unable or unwilling to escalate to parenteral PCAsa
• Escalating from oral to parenteral PCAs should be considered
for patients who are in FC IV, are having rapid progression,
have high‐risk hemodynamics, are at maximum‐tolerated
doses of all PH meds, or have right heart failure, and for
moderate‐risk patients with clinical worsening
Patient on triple therapy including an SQ/IV PCA
• Dose adjustment could be considered if the patient is not at
the maximally tolerated dose for all three medications
• Switching within the class could be considered for
intolerability and adherence issues
• Switching from a PDE5i to an sGC activator could be
considered if the patient is not improving or all medications
are at the maximum‐tolerated dosea
• Switching from SQ/IV treprostinil to IV epoprostenol could be
considered in very sick patients on a maximum‐tolerated dose
of treprostinil
• Referral for lung transplant evaluation in appropriate
candidates
Abbreviations: FC, functional class; PAH, pulmonary arterial hypertension;
PCA, prostacyclin analog; PDE5i, phosphodiesterase‐5 inhibitor; sGC,
soluble guanylate cyclase; SQ/IV, oral or infusion; WHO, World Health
Organization.
a

This switch has not been studied in patients on triple oral therapy.

prospective, randomized, open‐label, blinded endpoint
REPLACE trial suggests that this transition may benefit
some patients, although the open‐label design of this trial
limits the strength of the evidence it provides.4,5 Notably,
the REPLACE trial enrolled patients receiving PDE5i
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alone or in combination with an ERA, but not on triple
therapy. Note that the available sGC activator may cause
symptomatic hypotension and that three times daily
administration may be a barrier to adherence. These
considerations should be weighed in decisions about
switching to an sGC activator. A trial comparing an sGC
activator to a PDE5i in patients on triple therapy is
needed to clarify the role of sGC activators in patients at
high risk. The guidelines for PAH from the American
College of Chest Physicians recommend adding a third
class of PAH therapy for patients with WHO FC III or IV
symptoms who are deteriorating on dual therapy.22 This
recommendation aligns with our consensus for managing a patient on dual therapy, but was made before the
results of the REPLACE study were known.
This study has several limitations. The Delphi process
is inherently based on consensus rather than evidence,
and there are no generally accepted criteria for defining
consensus in Delphi studies. Studies have used a variety
of methods to define consensus, such as an agreement by
70% of panelists, cluster analysis, nominal group
technique, and the Likert scale criteria used here.6–14
In addition, as with any consensus‐based process, the
results may have been biased by panel selection and
questionnaire development.9,23–27 Panelists were drawn
from a limited geographic area (the United States) and
most are from large academic medical centers. Thus,
their recommendations may not be representative of
other areas or treatment centers, particularly those where
cost and access to care are problematic. Panelist
anonymity, which was maintained throughout the study,
helps prevent individuals from dominating the process,
but means that less experienced panelists are weighted
equally with more experienced ones and may increase
the risk that some participants responded without as
much depth of knowledge. To minimize this concern,
panelists were selected based on their generally recognized expertise in the subject area.

CONCLUSION
Careful consideration of multiple factors is required for
effective decision‐making on escalation and transitions of
therapy for patients with PAH. Broadly, switching agents
can be considered as a means to address issues of lack of
improvement or deterioration, tolerability, side effects, and
patient preference, but adding an agent or escalating from
oral to parenteral PCAs is essential when clinical improvement or risk reduction is needed in failing patients.
Switching from a PDE5i to an sGC activator may also be
a reasonable option for patients at low or intermediate risk
who fail to improve or deteriorate on PDE5i therapy.
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